{"id":"W2800067592","doi":"10.1007/s10637-018-0599-4","title":"A multicentre, open-label phase II study of Irinotecan, capecitabine (Xeloda®), and Oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma","year":2018,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency; Ottawa Hospital; University of Alberta; St. Michael's Hospital","funders":"Sanofi; Roche","keywords":"Medicine; Internal medicine; Gastroenterology; Irinotecan; Capecitabine; Phases of clinical research; Neutropenia; Oxaliplatin; Nausea; Febrile neutropenia; Clinical endpoint; Toxicity; Cancer; Surgery; Clinical trial; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002992037,0.002029568,0.003913145,0.0005896096,0.0007310048,0.001546539,0.001299622,0.001638014,0.003650233],"category_scores_gemma":[0.002309584,0.001175131,0.002563675,0.0008859809,0.002130531,0.00173944,0.0006442576,0.004834546,0.0008168747],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001608103,"about_ca_system_score_gemma":0.002447103,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00239017,"about_ca_topic_score_gemma":0.005410637,"domain_scores_codex":[0.998929,0.0005713803,0.00005068392,0.0002130132,0.00007457376,0.0001613748],"domain_scores_gemma":[0.9979766,0.0004070259,0.0003570381,0.0002046371,0.0001156306,0.0009390614],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9360898,0.04026883,0.003326262,0.0003067353,0.0009442505,0.00006291696,0.0001504739,0.0006834589,0.005117628,0.00006774433,0.0007656841,0.01221625],"study_design_scores_gemma":[0.7736484,0.2155923,0.00828085,0.00001422647,0.0006423521,0.00006550438,0.00005903178,0.0004491053,0.0004523364,0.00006716831,0.0007030202,0.00002574138],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9943158,0.001407001,0.0003777812,0.0003439897,0.0001974623,0.001724433,0.0007453667,0.00004608979,0.0008420916],"genre_scores_gemma":[0.9886197,0.001767915,0.001773927,0.0009697065,0.0004263541,0.002302852,0.00224274,0.00003523425,0.001861598],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003913145,"threshold_uncertainty_score":0.0158236,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04650012193401043,"score_gpt":0.3167996461221093,"score_spread":0.2702995241880988,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}